MCID: PRM127
MIFTS: 38

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Categories: Blood diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

MalaCards integrated aliases for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:

Name: Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type 58 17
Pcdlbcl,lt 58

Classifications:

Orphanet: 58  
Rare skin diseases
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C83.3
Orphanet 58 ORPHA178544

Summaries for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

MalaCards based summary : Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, also known as pcdlbcl,lt, is related to marginal zone b-cell lymphoma and diffuse large b-cell lymphoma. An important gene associated with Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are T cell receptor signaling pathway and Apoptosis Modulation and Signaling. The drugs Linagliptin and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include liver, b cells and lung, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Diseases related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Related Disease Score Top Affiliating Genes
1 marginal zone b-cell lymphoma 30.3 MYD88 IRF4
2 diffuse large b-cell lymphoma 29.8 MYD88 MYC IRF4 CDKN2A CD274
3 b-cell lymphoma 29.8 MYD88 MYC IRF4 CDKN2A CD274
4 mantle cell lymphoma 29.5 MYC CDKN2A CD274
5 lymphoma 29.4 MYD88 MYC IRF4 CDKN2A CD274
6 testicular lymphoma 29.4 PDCD1LG2 MYD88 IRF4 CD274
7 primary cutaneous b-cell lymphoma 10.5
8 primary cutaneous follicle center lymphoma 10.4
9 primary cutaneous lymphoma 10.4
10 rheumatoid arthritis 10.2
11 human herpesvirus 8 10.2
12 cutaneous t cell lymphoma 10.2
13 hereditary lymphedema i 10.2
14 ureteral benign neoplasm 10.2
15 polyneuropathy 10.2
16 poems syndrome 10.2
17 urticaria 10.2
18 skin disease 10.2
19 lymphomatoid granulomatosis 10.2
20 soft tissue sarcoma 10.2
21 encephalopathy 10.2
22 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 10.2
23 anogenital venereal wart 10.1 MYD88 CDKN2A
24 gray zone lymphoma 10.1 PDCD1LG2 CD274
25 autoimmune cardiomyopathy 10.1 PDCD1LG2 CD274
26 vulva squamous cell carcinoma 10.1 CDKN2A CD274
27 bladder squamous cell carcinoma 10.1 CDKN2A CD274
28 malignant spindle cell melanoma 10.1 CDKN2A CD274
29 lung non-squamous non-small cell carcinoma 10.1 PDCD1LG2 CD274
30 small cell carcinoma 10.1 CDKN2A CD274
31 gastroesophageal junction adenocarcinoma 10.1 PDCD1LG2 CD274
32 vulvar disease 10.1 CDKN2A CD274
33 anus cancer 10.1 CDKN2A CD274
34 acral lentiginous melanoma 10.1 CDKN2A CD274
35 myopathy, distal, 1 10.1 PDCD1LG2 CD274
36 mucosal melanoma 10.0 CDKN2A CD274
37 peritoneal mesothelioma 10.0 CDKN2A CD274
38 vulva cancer 10.0 CDKN2A CD274
39 pleural cancer 10.0 CDKN2A CD274
40 oropharynx cancer 10.0 CDKN2A CD274
41 myeloid sarcoma 10.0 IRF4 CD274
42 lymphoplasmacytic lymphoma 10.0 MYD88 IRF4
43 penile cancer 10.0 CDKN2A CD274
44 alk-negative anaplastic large cell lymphoma 9.9 MYC CD274
45 suppressor of tumorigenicity 3 9.8 MYC CDKN2A
46 plasmablastic lymphoma 9.8 MYC CDKN2A
47 rectum adenocarcinoma 9.8 MYC CD274
48 megaesophagus 9.8 MYC CDKN2A
49 supratentorial cancer 9.8 MYC CDKN2A
50 lung giant cell carcinoma 9.8 MYC CDKN2A

Graphical network of the top 20 diseases related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:



Diseases related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Symptoms & Phenotypes for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

MGI Mouse Phenotypes related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.8 CD274 CDKN2A IRF4 MYC MYD88 PDCD1LG2
2 homeostasis/metabolism MP:0005376 9.73 CD274 CDKN2A IRF4 MYC MYD88 PDCD1LG2
3 immune system MP:0005387 9.63 CD274 CDKN2A IRF4 MYC MYD88 PDCD1LG2
4 neoplasm MP:0002006 9.35 CDKN2A IRF4 MYC MYD88 PDCD1LG2
5 no phenotypic analysis MP:0003012 9.02 CD274 CDKN2A MYC MYD88 PDCD1LG2

Drugs & Therapeutics for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Drugs for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 341)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4 668270-12-0 10096344
2
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
3
Simethicone Approved Phase 4 8050-81-5
4
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
5
Lumefantrine Approved Phase 4 82186-77-4 6437380
6
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
7
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
8
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
9
Bromhexine Approved Phase 4 3572-43-8
10
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
11
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
12
Ribavirin Approved Phase 4 36791-04-5 37542
13
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
14
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
15
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
16
Bisoprolol Approved Phase 4 66722-44-9 2405
17
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
18
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
19
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
20
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
21
Norepinephrine Approved Phase 4 51-41-2 439260
22
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
23
Methylene blue Approved, Investigational Phase 4 61-73-4
24
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
25
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
26
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
27
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
28
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
29
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
30
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
31
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
32
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
33
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
34
Mycophenolic acid Approved Phase 4 24280-93-1 446541
35
tannic acid Approved Phase 4 1401-55-4
36
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
37 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
38
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
39
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
40
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
41
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
42
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
43
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
44
Epigallocatechin gallate Investigational Phase 4 989-51-5 65064
45
Epigallocatechin Experimental, Investigational Phase 4 970-74-1 72277
46
Cobalamin Experimental Phase 4 13408-78-1 6857388
47
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
48 Calamus Phase 4
49 Antiparasitic Agents Phase 4
50 Antiprotozoal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 372)
# Name Status NCT ID Phase Drugs
1 Open Label, Multicenter, Non-comparative Study to Evaluate the Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients. Unknown status NCT01766518 Phase 4 Mycophenolate mofetil
2 Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients Unknown status NCT02280174 Phase 4 linagliptin
3 SMALL BOWEL CLEANSING FOR CAPSULE ENDOSCOPY IN PEDIATRIC PATIENTS: A PROSPECTIVE RANDOMIZED SINGLE-BLINDED STUDY Unknown status NCT01783782 Phase 4 polyethylene glycol 4000 solution with simethicon;simethicon
4 Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
5 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
6 Home Oxygen Therapy in the Ambulatory Treatment of Bronchiolitis Unknown status NCT01216553 Phase 4
7 Phase 4 Study of Effects of Montelukast Treatment on Allergic Inflammation in Children With and Without Food Allergy, Single Centered, Randomised, Double Blind, Placebo Controlled Parallel Group Cross-over Study Completed NCT01618929 Phase 4 Montelukast
8 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4 Cyclosporine;Tacrolimus
9 Immune Response After Inactivated Oral Cholera Vaccine (Dukoral) in Renal Transplant Recipients Completed NCT01109914 Phase 4
10 The Polyphenol Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism During Graded Exercise in Man. Completed NCT03199430 Phase 4
11 Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Completed NCT03800264 Phase 4 Bisoprolol
12 Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine Completed NCT03354572 Phase 4 Acetyl cysteine;Placebos
13 Phase 4: Study of Ketamine Inhibition of Interleukin 6 in Hepatic Resections Requiring Temporary Porto-arterial Occlusion Completed NCT00978757 Phase 4 Ketamine
14 Phase 2 Randomized Multicenter Controlled Study of Ribavirin Pre-treatment (8 Weeks) Followed by Standard Therapy With Ribavirin and Pegylated Interferon (48 Weeks) in Transplanted Patients With Recurrence of Chronic Hepatitis C Completed NCT00993122 Phase 4 ribavirin pre-treatment
15 An Open Label Evaluation of MIDI to Quantify Performance Change in Subjects With Musician's Dystonia After Treatment With Botulinum Toxin Type B (Myobloc ®). Completed NCT00208091 Phase 4 Botulinum toxin, type B
16 Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation: A Randomized Controlled Study Recruiting NCT03522688 Phase 4 Dexmedetomidine
17 Use of HA 330-II for Hemofiltration in Patients With Acute Liver Failure as a Bridge to Liver Transplantation: Clinical Evaluation Protocol. Recruiting NCT04243655 Phase 4 Standard medical treatment (SMT)
18 The Efficacy of Intravenous Hydroxocobalamin Versus Methylene Blue as Treatment for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients Recruiting NCT04054999 Phase 4 Hydroxocobalamin;Methylene Blue
19 A Study in Adults on Pre LT Dialysis With Basiliximab, Delayed Tacrolimus (TAC), Mycophenolate (MMF), Steroids (Grp 1) vs. Basiliximab, Delayed TAC, MMF, Steroids, With Everolimus 30d Post LT(Grp 2), vs. TAC, MMF, Steroids (Grp 3). Not yet recruiting NCT04104438 Phase 4 Basiliximab 20 MG
20 Somatostatin as Inflow Modulator in Adult-to-adult Living Donor Liver Transplantation: a Randomized, Double-blind, Placebo-controlled Trial Not yet recruiting NCT04107428 Phase 4 Somatostatin;Placebo
21 Prehospital Laryngeal Tube vs. Bag-Valve Mask Ventilation Used by Paramedics During CPR- A Prospective, Controlled, Randomised, Multi-center Trial Terminated NCT01718795 Phase 4
22 Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study Withdrawn NCT00625469 Phase 4 bosentan
23 Randomized Placebo-Controlled Study of Sildenafil For The Treatment of Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis: A Pilot Study Withdrawn NCT00625079 Phase 4 sildenafil
24 Investigator Sponsored Research Proposal : Efficacy and Safety of Combination Ambrisentan and TadaLafil in PATiEnts With PortoPulmonary Hypertension (ESCALATE-PPH) Withdrawn NCT03309592 Phase 4 Ambrisentan Pill;Tadalafil Pill
25 Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Developed Cooperatively by YunNan Walvax Biotechnology Co., Lt and Yuxi Walvax Biotechnology Co., Lt Among 2-71 Months (the Youngest Could be 6 Weeks) Healthy Infants and Toddlers by Randomized Blind Method With Similar Control in Multi-centers. Unknown status NCT02736240 Phase 3
26 A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase II Trial to Evaluate Late Introduction of Cyclosporine or Everolimus Versus a 5-day Delay of Cyclosporine in Combination With MMF in Liver Transplant Recipients With MELD-Scores≥25 Unknown status NCT01023542 Phase 2, Phase 3 delayed, low-dose CNI;BU-CNI;BU-Everolimus
27 Boceprevir Treatment in Liver Pre-transplant HCV Patients Unknown status NCT02160080 Phase 3 Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
28 Effect of Intermittent Hepatic Inflow Occlusion During Donor Hepatectomy In Adult Living Donor Liver Transplantation Using Right Hemiliver Grafts Unknown status NCT01171742 Phase 3
29 Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Rectal Anterior Resection for Rectal Cancer Patients Unknown status NCT01861678 Phase 3
30 Cognitive-behavioral Therapy vs. Light Therapy for Preventing Seasonal Affective Disorder Recurrence Unknown status NCT01714050 Phase 2, Phase 3
31 Donepezil as Add-On Treatment of Psychotic Symptoms in Patients With Dementia of the Alzheimer's Type Unknown status NCT00190021 Phase 3 donepezil
32 Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 48-weeks Treatment With Gastro-resistant Phosphatidylcholine (LT-02) Versus Placebo Versus Mesalamine for Maintenance of Remission in Patients With Ulcerative Colitis Completed NCT02280629 Phase 3 LT-02;Placebo;Mesalamine
33 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise Completed NCT00316082 Phase 3 Saxagliptin;Saxagliptin;Saxagliptin;Saxagliptin;Placebo;metformin
34 A Double-Blind, Double-Dummy, Randomized, Active-Comparator, Non-Inferiority Study of LT-NS001 Versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulcer Rates Completed NCT01063920 Phase 2, Phase 3 LT-NS001;Naprosyn®
35 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise Completed NCT00121641 Phase 3 Saxagliptin;Saxagliptin;Saxagliptin;Placebo matching Saxagliptin;Metformin;Placebo matching Metformin;Saxagliptin;Metformin
36 A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control Completed NCT00327015 Phase 3 Saxagliptin;Saxagliptin;Metformin;Placebo;pioglitazone
37 A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone Completed NCT00313313 Phase 3 Saxagliptin;Saxagliptin;Glyburide;Placebo;Glyburide;Metformin
38 A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS477118) in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone Completed NCT00295633 Phase 3 Saxagliptin;Saxagliptin;Placebo;pioglitazone;rosiglitazone;metformin
39 "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone" Completed NCT00121667 Phase 3 Saxagliptin + Metformin;Saxagliptin + Metformin;Saxagliptin + Metformin;Placebo + Metformin;Pioglitazone
40 A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System Completed NCT00993681 Phase 3
41 Mechanism of Action and Efficacy of Saxagliptin (BMS-477118) in the Treatment of Type 2 Diabetic Patients Completed NCT00374907 Phase 3 Saxagliptin;Placebo;Metformin (blinded);Metformin (open-label)
42 Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT) Completed NCT00256750 Phase 3 Cyclosporine (CsA);Belatacept LI (less intensive);Belatacept MI (more intensive)
43 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode. CN138-146 LT is the 26-week Open Label Extension Phase of the Above Titled Protocol, CN138-146 ST. Completed NCT00094432 Phase 3 Aripiprazole;Placebo
44 Acupuncture for Dry Eye Syndrome : A Randomized, Patient-Assessor Blinded, Non-acupuncture Point Shallow Penetration-Controlled Study Completed NCT00969280 Phase 3
45 "A Prospective, Randomized Controlled Clinical Investigation of MAVERICK™ Total Disc Replacement in Patients With Degenerative Disc Disease" Completed NCT00635843 Phase 3
46 An Unicenter, Prospective, Randomized, Pilot Study Comparing the Effect of Everolimus-containing Versus mTOR Inhibitor Free Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation. Completed NCT01707849 Phase 3 EVL arm;MMF arm
47 Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy. Completed NCT01654731 Phase 3 Bezafibrate;placebo
48 ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension Completed NCT00777920 Phase 3 Ambrisentan
49 Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant Completed NCT00466219 Phase 3 Ribavirin;Pegylated interferon alpha2a
50 PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial: A Randomized Controlled Trial of Gonadotropin Releasing Hormone Agonist (GnRHa) for Fertility Preservation in Oncology Patients Completed NCT00380406 Phase 3 Leuprolide acetate

Search NIH Clinical Center for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Genetic Tests for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Anatomical Context for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

MalaCards organs/tissues related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:

40
Liver, B Cells, Lung, Bone, Spinal Cord, Kidney, Endothelial

Publications for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Articles related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:

(show top 50) (show all 107)
# Title Authors PMID Year
1
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: A Case Report. 61
32566435 2020
2
Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives. 61
32521744 2020
3
18FDG PET/CT in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. 61
32209875 2020
4
A case of a primary cutaneous diffuse large B-cell lymphoma, leg type. 61
31884690 2020
5
Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type. 61
32238727 2020
6
Challenges in Assessing MYC Rearrangement in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. 61
31764222 2020
7
Diffuse large B-cell lymphoma variants: an update. 61
31735345 2020
8
A Unique Presentation of Cutaneous Diffuse Large B-Cell Lymphoma. 61
32318298 2020
9
Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type. 61
31566707 2019
10
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. 61
31150604 2019
11
Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib. 61
31446456 2019
12
Acquired N-Linked Glycosylation Motifs in B-Cell Receptors of Primary Cutaneous B-Cell Lymphoma and the Normal B-Cell Repertoire. 61
31042459 2019
13
Primary cutaneous B-cell lymphoma: narrative review of the literature. 61
29144099 2019
14
Widespread primary cutaneous diffuse large B-cell lymphoma, leg type, with nasal involvement. 61
31099459 2019
15
A rare case of primary cutaneous diffuse large B-cell lymphoma, leg type in a patient with chronic lymphedema of the leg. 61
31361244 2019
16
Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type. 61
31110725 2019
17
Primary cutaneous diffuse large B-cell lymphoma, leg type, localized in the right periorbital region. 61
30230576 2019
18
Cutaneous B-Cell Lymphoma. 61
30497672 2019
19
[Primary skin lymphomas: Current therapy]. 61
30709635 2019
20
CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type. 61
30792929 2019
21
High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. 61
30113335 2018
22
Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management. 61
30039522 2018
23
Primary Cutaneous Follicle Center Lymphoma. 61
30407851 2018
24
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. 61
29596904 2018
25
A rare case of primary cutaneous diffuse large B-cell lymphoma, leg type. 61
30372723 2018
26
Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. 61
29581544 2018
27
Spontaneous Regression of Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type. 61
29508000 2018
28
Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy. 61
29899297 2018
29
Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response. 61
29693055 2018
30
PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. 61
29112015 2018
31
Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type. 61
28838616 2017
32
Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. 61
28543967 2017
33
Relapsed Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type. 61
29263555 2017
34
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Spontaneous Regression After Biopsy. 61
28926365 2017
35
Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. 61
28479318 2017
36
Primary Cutaneous B-cell Lymphomas. 61
28802500 2017
37
Spontaneous regression of a primary cutaneous diffuse large B-cell lymphoma, leg type. 61
27374170 2017
38
Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma. 61
28065463 2017
39
Cutaneous lymphoma misdiagnosed as chronic lymphadenitis. 61
25903778 2016
40
Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management. 61
27650702 2016
41
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. 61
27665744 2016
42
TOX expression in cutaneous B-cell lymphomas. 61
27180090 2016
43
An 88-year-old woman with an ulcerous tumour on the leg. Primary cutaneous diffuse large-B-cell lymphoma, leg type. 61
26951356 2016
44
Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. 61
26788279 2015
45
Rare case of primary cutaneous diffuse large B-cell lymphoma-leg type with testicular infiltration. 61
26881687 2015
46
Skin Involvement of Mantle Cell Lymphoma May Mimic Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type. 61
26034867 2015
47
(18)FDG PET/CT appearance in primary cutaneous diffuse large B-cell lymphoma, leg type. 61
25742229 2015
48
Atypical clinicopathologic presentation of primary cutaneous diffuse large B-cell lymphoma, leg type. 61
25824272 2015
49
Primary cutaneous diffuse large B cell lymphoma, leg type (PCDLBCL-LT) in the setting of prior radiation therapy. 61
25326162 2015
50
Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea. 61
25552248 2015

Variations for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Cosmic variations for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88392041 NOTCH2 haematopoietic and lymphoid tissue,leg,lymphoid neoplasm,diffuse large B cell lymphoma c.7308G>A p.W2436* 1:119915414-119915414 0

Expression for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Search GEO for disease gene expression data for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Pathways for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Pathways related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.04 MYD88 IRF4 CD274
2
Show member pathways
11.88 MYD88 MYC IRF4 CDKN2A
3 11.44 PDCD1LG2 MYD88 IRF4 CD274
4 11.23 MYC CDKN2A
5
Show member pathways
10.6 MYC CDKN2A
6 10.5 MYC CDKN2A

GO Terms for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Biological processes related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.72 MYD88 MYC CDKN2A
2 cell surface receptor signaling pathway GO:0007166 9.63 PDCD1LG2 MYD88 CD274
3 cytokine-mediated signaling pathway GO:0019221 9.61 MYD88 MYC IRF4
4 immune system process GO:0002376 9.56 PDCD1LG2 MYD88 IRF4 CD274
5 type I interferon signaling pathway GO:0060337 9.54 MYD88 IRF4
6 positive regulation of T cell proliferation GO:0042102 9.52 PDCD1LG2 CD274
7 positive regulation of smooth muscle cell proliferation GO:0048661 9.51 MYD88 MYC
8 T cell costimulation GO:0031295 9.49 PDCD1LG2 CD274
9 negative regulation of T cell proliferation GO:0042130 9.48 PDCD1LG2 CD274
10 positive regulation of DNA binding GO:0043388 9.4 MYC IRF4
11 negative regulation of interferon-gamma production GO:0032689 9.37 PDCD1LG2 CD274
12 cellular response to lipopolysaccharide GO:0071222 9.33 PDCD1LG2 MYD88 CD274
13 defense response to protozoan GO:0042832 9.32 MYD88 IRF4
14 negative regulation of activated T cell proliferation GO:0046007 8.96 PDCD1LG2 CD274
15 negative regulation of interleukin-10 production GO:0032693 8.62 PDCD1LG2 CD274

Molecular functions related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 8.8 MYC IRF4 CDKN2A

Sources for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....